Lake Street Capital Boosts Personalis (NASDAQ:PSNL) Price Target to $9.00

Personalis (NASDAQ:PSNL) had its price objective boosted by Lake Street Capital from $7.00 to $9.00 in a research note released on Wednesday,Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

Other equities analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a “buy” rating and set a $7.25 price objective on shares of Personalis in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Personalis in a research note on Wednesday.

Personalis Price Performance

Shares of PSNL opened at $5.60 on Wednesday. The firm has a 50 day simple moving average of $4.69 and a two-hundred day simple moving average of $4.32. Personalis has a one year low of $1.12 and a one year high of $7.20. The company has a market cap of $395.63 million, a P/E ratio of -3.33 and a beta of 1.75.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.31). The business had revenue of $25.71 million for the quarter, compared to the consensus estimate of $20.67 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. During the same quarter in the prior year, the company earned ($0.51) earnings per share. On average, analysts expect that Personalis will post -1.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Personalis

Several hedge funds have recently added to or reduced their stakes in PSNL. nVerses Capital LLC acquired a new position in Personalis in the 3rd quarter valued at approximately $40,000. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its holdings in Personalis by 42.5% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock valued at $81,000 after purchasing an additional 4,504 shares during the period. International Assets Investment Management LLC raised its position in Personalis by 438.0% during the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock worth $113,000 after purchasing an additional 17,082 shares during the last quarter. Quantbot Technologies LP bought a new position in Personalis during the 3rd quarter worth $210,000. Finally, Barclays PLC lifted its holdings in Personalis by 45.4% during the 3rd quarter. Barclays PLC now owns 65,468 shares of the company’s stock worth $352,000 after buying an additional 20,444 shares during the period. 61.91% of the stock is currently owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.